SEC Form 4 · accession 0001615774-16-004291
ANAVEX LIFE SCIENCES CORP. · AVXL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Elliot Favus
Director
Period of report
Apr 2, 2015
Accepted (ET)
Feb 23, 2016 · 2:33 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001314052
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option/Right to BuyF1,F3,F4 | $0.92 | Apr 2, 2015 | A | 50,000 | A | Apr 2, 2015 | — | Common Stock | 50,000 | 87,500 | D |
| Stock Option/Right to BuyF2,F3,F4 | $1.68 | Dec 31, 2015 | A | 4,500 | A | Dec 31, 2015 | — | Common Stock | 4,500 | 92,000 | D |
Explanation of responses
- F1Reporting person was granted options to purchase the equivalent of 50,000 shares of Common Stock. The options vest in three equal installments on April 2, 2015, April 2, 2016 and April 2, 2017. 16,667 of these options have vested as of the date of this filing. Initially, 200,000 options were granted which were adjusted to 50,000 options to reflect a 1-for-4 reverse stock split effected on October 6, 2015.
- F2Pursuant to the Company's current obligation to grant to Dr. Favus options to purchase 1,500 shares at the end of each fiscal quarter as compensation for service on Board Committees, an aggregate of 4,500 options were granted to Dr. Favus for quarters ended June 30, 2015, September 30, 2015 and December 31, 2015, which options vested on December 31, 2015.
- F3Includes options to purchase 37,500 shares of common stock at an exercise price of $1.20, to vest annually over a three year period commencing May 7, 2015, 12,500 of which have vested. Initially, 150,000 options were granted which were adjusted to 37,500 options to reflect a 1-for-4 reverse stock split effected on October 6, 2015.
- F4N/A